Mocetinostat(MGCD0103)
Catalog No: 111015
CAS Number: 726169-73-9
Purity: 98% by HPLC/HNMR
Mocetinostat is an orally-bioavailable, spectrum-selective HDAC inhibitor. Mocetinostat has completed 13 clinical trials in more than 400 patients with a variety of hematologic malignancies and solid tumors. Mirati is currently conducting Phase 2 studies of mocetinostat as a single agent in patients with bladder cancer and DLBCL.
Mirati retains worldwide rights to mocetinostat with the exception of certain Asian territories where the program is partnered with Taiho.
For research use only. We do not sell to patients.
Chemical Information
| Name | Mocetinostat(MGCD0103) |
|---|---|
| Iupac Chemical Name | N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide |
| Molecular Formula | C23H20N6O |
| Molecular Weight | 396.44 |
| Smile | O=C(NC1=CC=CC=C1N)C2=CC=C(CNC3=NC=CC(C4=CC=CN=C4)=N3)C=C2 |
| InChiKey | HRNLUBSXIHFDHP-UHFFFAOYSA-N |
| InChi | InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29) |
| CAS Number | 726169-73-9 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | crystalline solid |
|---|---|
| Purity | 98% by HPLC/HNMR |
| Storage | 3 years -20ºCpowder 6 months-80ºCin solvent |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature. |
| HS Code |
Coming soon.
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
Not available
Chemical Structure
-cas-726169-73-9.png)